DiaMedica Therapeutics Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- DiaMedica Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $135.00K, a 17.18% decline year-over-year.
- DiaMedica Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $420.00K, a 346.81% increase year-over-year.
- DiaMedica Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $465.00K, a 269.05% increase year-over-year.
- DiaMedica Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $163.00K, a 2228.57% increase year-over-year.
- DiaMedica Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $1.00M, a 292.19% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $256.00K.
- DiaMedica Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $244.00K, a 440.29% increase from fiscal 2020.
- DiaMedica Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $45.16K, a 39.79% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $135.00K 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $420.00K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $1.00M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $465.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $163.00K 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $94.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $256.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $126.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $7.00K 10-Q · filed 2025-11-12 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $244.00K 10-K · filed 2023-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $273.16K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $273.16K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-03-31 | $244.00K 10-Q · filed 2022-11-09 | $273.16K derived: sum of 4 quarters · filed 2022-11-09 |
| 2020-12-31 | $29.16K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $45.16K 10-K · filed 2022-03-14 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | |
| 2020-03-31 | $16.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $75.00K 10-K · filed 2021-03-10 | |
| 2019-06-30 | $75.00K 10-Q · filed 2020-11-04 | |
| 2018-12-31 | $43.00K 10-K · filed 2020-03-23 | |
| 2017-12-31 | $7.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |